Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT05280470 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: Ifinatamab Deruxtecan (I-DXd)

Sponsor

Daiichi Sankyo

Collaborators

[object Object]